A Q&A with Dr. Ganesh Bala on LC–MS and Multi-Attribute Methods for Bioconjugate CQA Monitoring

Why It Matters

MAM‑based LC‑MS streamlines bioconjugate analytics, cutting cycle time and cost while improving data fidelity, a critical advantage as ADCs and AOCs dominate oncology and rare‑disease pipelines.

Key Takeaways

• MAM LC‑MS enables simultaneous quantification of PTMs and conjugation sites
• Site‑specific peptide mapping improves detection of heterogeneity in ADCs
• Integrated workflow cuts assay time and analytical burden across development
• Faster, consistent data supports regulatory submissions and comparability studies
• Precision medicine drives demand for complex bioconjugates like ADCs and AOCs

Pulse Analysis

The biopharma landscape is rapidly shifting from traditional monoclonal antibodies to more sophisticated formats such as antibody‑drug conjugates (ADCs) and antibody‑oligonucleotide conjugates (AOCs). These modalities promise higher potency and targeted delivery, especially in oncology and rare diseases, but they also introduce structural complexity that challenges conventional quality‑control methods. Variable conjugation sites, fluctuating drug‑to‑antibody ratios, and novel degradation pathways create a heterogeneous product profile that must be characterized with high precision to ensure safety and efficacy.

Multi‑attribute methods (MAMs) built on LC‑MS peptide mapping address these challenges by delivering site‑specific, quantitative data in a single assay. The technique separates peptides chromatographically, then measures their masses with high‑resolution mass spectrometry, capturing post‑translational modifications, sequence variants, and conjugation features simultaneously. This integrated approach reduces the need for multiple orthogonal tests, improves sensitivity to subtle changes, and maintains the throughput required for manufacturing release and comparability studies. Moreover, the rich data set supports deeper structure‑function insights, informing both process development and regulatory documentation.

From a business perspective, adopting MAM‑based workflows accelerates development timelines and lowers analytical costs, directly impacting time‑to‑market for high‑value bioconjugates. Faster, more reliable data enables earlier decision‑making, smoother scale‑up, and stronger regulatory dossiers, which are essential in a competitive market where speed and data integrity are differentiators. As precision medicine continues to drive demand for complex therapeutics, platforms like Agilent’s MAM will become indispensable for companies seeking to maintain quality while scaling innovative drug candidates.